type 2 diabetes
Conditions
Interventions
Mitiglinide 10mg three times daily will be added for 4 months. If the glycemic control are suboptimal (HbA1c(JDS) 6.5% or more) 2 month after the treatment, the patients will be treated with mitiglini
Sponsors
Keio University School of Medicine Department of Medicine Division of Nephrology, Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes inadequately controlled (HbA1c 6.5% or more) with diet therapy or non-insulin secretagogues
Exclusion criteria
Exclusion criteria: 1) Patients with pretreatment with sulfonyl urea within 3 months 2) Patients who need insulin therapy for the treatment of type 2 diabetes 3) Patients with severe liver dysfunction (AST and/or ALT 100IU/l or more) 4) Patients with severe renal dysfunction (Cr 2.5mg/dl or more) or patients under hemodialysis 5) Patients with uncontrolled hypertension (SBP 180mmHg or more, and/or DBP 110mmHg or more) 6) Patients with severe heart disease 7) Patients with onset of cardiovascular disease within 3 months 8) Patients with malignancy 9) Patients with allergy for glinide 10) Patients with pregnancy 11) Patients whom the doctors do not allow to participate the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | — |
Secondary
| Measure | Time frame |
|---|---|
| fasting plasma glucose, C-peptide, insulin, proinsulin, glycoalbumin, 1,5-AG, serum lipid profile, body weight, adverse events, oxidative stress markers, inflammatory markers, daily capillary glucose profile | — |
Countries
Japan
Contacts
Public ContactYoshifumi Saisho
Keio University School of Medicine Department of Medicine
Outcome results
None listed